— Know what they know.
Not Investment Advice

JNCE NASDAQ

Jounce Therapeutics, Inc.
1W: -2.6% 1M: -1.1% 3M: +55.4% 1Y: -64.0% 3Y: -64.8% 5Y: -90.7%
$1.88
Last traded 2023-05-05 — delisted
NASDAQ · Healthcare · Biotechnology · $99.0M mcap · 30M float · 11.63% daily turnover

Cash Flow Trends

Operating Cash Flow
-$29M +65.4% ▲
Capital Expenditures
$919K -146.4% ▼
5Y CAGR: -42.9%
Free Cash Flow
-$30M +64.5% ▲
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
$55M +205.9% ▲

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2018FY2019FY2020FY2021FY2022
— Operating Activities —
Net Income-$27M$57M-$44M-$91M-$51M
Depreciation & Amort.$4M$4M$3M$3M$2M
Stock-Based Comp.$9M$10M$10M$11M$10M
Change in Working Capital-$48M-$99M$3M-$8M$9M
Other Non-Cash Items-$1M-$1M$47K$921K$800K
Operating Cash Flow-$64M-$30M-$28M-$83M-$29M
— Investing Activities —
Capital Expenditures-$1M-$985K-$94K-$373K-$919K
Acquisitions (Net)$0$0$0$0$0
Investment Purchases-$253M-$189M-$86M-$130M-$25M
Investment Sales$341M$221M$137M$70M$109M
Other Investing$0$0$0$0$0
Investing Cash Flow$86M$31M$51M-$61M$83M
— Financing Activities —
Net Debt Issuance$0$0$0$0$0
Stock Repurchased$0$0$56M$0$0
Dividends Paid$0$0$0$0$0
Other Financing$2M$4M$71M$92M$442K
Financing Cash Flow$2M$4M$71M$92M$442K
Net Change in Cash$24M$5M$94M-$52M$55M
Cash End of Period$49M$55M$149M$97M$152M
Free Cash Flow-$65M-$31M-$28M-$84M-$30M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms